CTRI/2019/07/020407尚未招募未知
STOP IMATINIB MESYLATE IN PATIENTS OF CHRONIC MYELOID LEUKEMIA- CHRONIC PHASE(CML-CP)- A PILOT STUDY. - ISTIM
DR BRA IRCH AIIMS0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •a). Age >= 18 years
- •b). CML-CP on imatinib mesylate
- •c). Optimal response to imatinib
- •d). Minimum duration of imatinib mesylate treatment of 3 years
- •e) At least complete molecular remission MR4
- •f). Deep molecular remission duration should be at least one year
- •g) Baseline data and documentation of treatment should be available for outside treated patients
排除标准
- •a) Patients who had CML-accelerated phase/ blast crisis at diagnosis
- •b) High Sokal score
- •c). Not willing for the study
- •d) Pregnancy
- •e) Female patient not willing to use contraception
- •f) Patients not willing for regular follow up
研究者
相似试验
招募中
2 期
Imatinib discontinuation for Chronic Myelogenou Leukemia-Chronic Phase with 2 years complete molecular remission.Chronic Myelogenou Leukemia-Chronic Phase who have maintained complete molecular remission for at least 2 years.JPRN-UMIN000012472Epidemiological and Clinical Research Information Network (ECRIN)100
已完成
2 期
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib in Japan adult leukemia study group studyChronic Myeloid Leukemia Chronic phaseJPRN-UMIN000011971Japan Adult Leukemia Study Group62
招募中
不适用
Stop imatinib or dasatinib study in CP-CML patients mainitaining complete molecular response for two yearschronic phase chronic myeloid leukemiaJPRN-UMIN000007944Tokyo Women's Medical University40
已完成
2 期
Dasatinib discontinuation for Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission.chronic myeloid leukemiaJPRN-UMIN000005130Epidemiological and Clinical Research Information Network (ECRIN)50
进行中（未招募）
1 期
Arrest Imatinib or Dasatinib in CML patients with Deep Molecular ResponsesChronic phase CML patients with BCR-ABL/ABLIS transcript levels below MR3 (<0.1%) and aboveMR4.5 (>0.0032%) at the time of accrual.MedDRA version: 20.0Level: LLTClassification code 10009015Term: Chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2014-001603-42-ITAIL CATANIA ASSOCIAZIONE ITALIANA CONTRO LEUCEMIE-LINFOMI E MIELOMA ONLUS222